Search Results for “cancer” – Page 53 – media

the Mayo Clinic experience

Immune checkpoint inhibitors have revolutionized the treatment of advanced malignancies. By blocking T-cell inhibition these drugs result in immune targeting of tumor cells and normal tissue. As such, their main toxicity is inducing immune-mediated tissue damage.
- Source: acrabstracts.org
- 486
- January 30, 2018
inhibitor malignancies Researches
New nanomedicine could prevent progression of pancreatic cancer

A new study published in scientific journal Nature Communications distinguishes the reason for extended pancreatic cancer survival: an inverse correlation between a known oncogene, a gene that promotes the development of cancer, and the expression of an oncosuppressor microRNA.
- Source: Israel21c
- 564
- January 30, 2018
cancer medtech pancreatic Researches
Boosting cancer therapy with cross-dressed immune cells

Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods. Immunotherapies are breakthrough treatments that stimulate the patient’s immune cells to attack the tumor through the recognition of aberrant molecules called tumor antigens. They can be very effective, but currently can only cure a minority of patients with solid tumors. Researchers and physicians are now looking into ways of increasing the precision and strength of the immune attack on the tumor. Dendritic cell vaccines One approach is the “dendritic cell vaccine”. Dendritic cells are specialized immune cells whose role is to capture antigens from foreign bodies and present them to the immune system’s killer T cells, which will then attack and destroy the invaders. For the vaccine, dendritic cells are taken out of the patient, “force-fed” with tumor antigens, and finally re-injected back into ...
- Source: medicalxpress
- 578
- January 25, 2018
artificial molecules cancer tumor immunotherapies Researches
Merck KGaA taps UK cancer research organizations to feed pipeline

After an R&D drought that lasted more than a decade, Merck KGaA may be coming out of the desert. Following two recent drug approvals, including the landmark FDA OK for checkpoint inhibitor Bavencio, the German Merck is now entering an R&D collaboration that might help fill its pipeline with new cancer drug contenders.
- Source: Endpts
- 554
- January 23, 2018
Bavencio cancer inhibitor Market Views
Modification of the Associations Between Duration of Oral Contraceptive Use and Ovarian, Endometrial, Breast, and Colorectal Cancers

Findings In this population-based cohort study of more than 100, 000 predominantly postmenopausal women, risk reductions for ovarian cancer associated with increasing duration of oral contraceptive use were generally consistent across health behaviors. For endometrial cancer, the reductions were strongest among current smokers, obese women, and those who exercised rarely; lack of associations with breast and colorectal cancer were consistent across health behaviors.
- Source: Jamanetwork
- 509
- January 22, 2018
cancer oral contraceptive use Researches
Blood cancer care needs improving, finds MP inquiry

The Government’s 2015 Cancer Strategy is failing to support blood cancer patients in the UK and care must improve, an MP inquiry has found.
- Source: pharmatimes
- 643
- January 19, 2018
blood cancer NHS polices
Afatinib Approval Expanded for Rare Lung Cancer Treatment

Boehringer Ingelheim announced the approval of a new indication for afatinib (Gilotrif), as the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (NDA) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
- Source: Raredr
- 705
- January 17, 2018
afatinib DNA FDA New Approvals NSCLC
AstraZeneca’s PARP inhibitor gains market edge with breast cancer approval

AstraZeneca still enjoys the perks of being first to market with its PARP inhibitor. Lynparza (olaparib) sales were $81 million from July to September, whereas net revenues were $16.8 million and $39.4 million for Clovis Oncology Inc.'s Rubraca (rucaparib) and Tesaro Inc.'s Zejula (niraparib), respectively.
- Source: Biopharmadive
- 578
- January 17, 2018
inhibitor Lynparza New Approvals
Immune Cells Play Key Role in Early Breast Cancer Metastasis Even Before a Tumor Develops

Mount Sinai researchers have discovered that normal immune cells called macrophages, which reside in healthy breast tissue surrounding milk ducts, play a major role in helping early breast cancer cells leave the breast for other parts of the body, potentially creating metastasis before a tumor has even developed, according to a study published in Nature Communications.
- Source: mountsinai.org
- 538
- January 16, 2018
breast cancer macrophages Researches
FDA approves first treatment for breast cancer with a certain inherited genetic mutation

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test, called the BRACAnalysis CDx.
- Source: finance.yahoo
- 545
- January 15, 2018
breast cancer Lynparza metastasized New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.